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The aim of this satellite workshop held at the 17th World Congress of Basic and Clinical
Pharmacology (WCP2014) was to discuss the needs, optimal methods and practical
approaches for extending education and teaching of medicines development, regulation,
and clinical research to Low and Middle Income Countries (LMICs). It was generally
agreed that, for efficiently treating the rapidly growing number of patients suffering
from non-communicable diseases, modern drug therapy has to become available more
widely and with a shorter time lag in these countries. To achieve this goal many
additional experts working in medicines development, regulation, and clinical research
have to be trained in parallel. The competence-oriented educational programs designed
within the framework of the European Innovative Medicine Initiative-PharmaTrain (IMI-
PhT) project were developed with the purpose to cover these interconnected fields.
In addition, the programs can be easily adapted to the various local needs, primarily
due to their modular architecture and well defined learning outcomes. Furthermore, the
program is accompanied by stringent quality assurance standards which are essential
for providing internationally accepted certificates. Effective cooperation between inter-
national and local experts and organizations, the involvement of the industry, health
care centers and governments is essential for successful education. The initiative should
also support the development of professional networks able to manage complex health
care strategies. In addition it should help establish cooperation between neighboring
countries for jointly managing clinical trials, as well as complex regulatory and ethical
issues.
Keywords: pharmaceutical medicine, clinical trials, regulatory agencies, low and middle income countries,
competencies, learning outcomes
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Introduction
Global educational efforts appropriately focused according to
local needs are required for supporting science-based ratio-
nal therapy with conventional and biological agents, vaccines,
and drug-medical device combinations worldwide. The 17th
World Congress of Basic and Clinical Pharmacology in Cape
Town, South Africa offered a unique opportunity to discuss
with experts working in differently developed environments
the current state and challenges of education and training
for medicine development, regulation, and clinical research in
Low and Middle Income Countries (LMICs). The goals were
to understand and appraise the magnitude of the educational
needs of lesser developed countries and to formulate teach-
ing concepts for covering the identified topics in the respec-
tive scientific fields. Finally, the practical approach and finan-
cial backing needed to realize such programs were discussed
to appraise possible risks involved. The satellite workshop was
organized in cooperation with the Fundisa African Academy of
Medicines Development and the Hungarian Society for Exper-
imental and Clinical Pharmacology, under the joint scien-
tific auspices of the Innovative Medicine Initiative-PharmaTrain
project [IMI-PhT] (2015) and the International Federation of
Associations of Pharmaceutical Physicians and Pharmaceutical
Medicine [IFAPP] (2015). The lecturers were selected to represent
regional experts working at local universities, regulatory agen-
cies, pharmaceutical companies and other organizations. Other
speakers were recruited from PhT course providers and IFAPP
member organizations engaged in educational activities in var-
ious regions of the world. The topics of the workshop were
divided into five subject areas which will be discussed separately
below.
Workshop Topics
Educational Needs of a Changing Health Care
Environment in LMIC’s
Over the past 5 years the educational programs of the various
medicine development courses offered in Europe were updated
and harmonized within the IMI-PhT project. For this education
program the entiremedicines development process frommolecule
to marketplace and health care application was captured in a syl-
labus containing 180 topics (PhT Syllabus; PharmaTrain, 2015b).
The topics were organized into six basic modules which can be
presented in 3–4 days at suitable intervals such that students
may attend the course alongside full time employment. Sixty
learning outcomes were specified which have to be mastered by
the students to fulfill the competency requirements for becoming
an expert in medicine development. The learning outcomes are
considered to be the backbone for harmonizing the education pro-
gram of the different course providers. Many similarly structured
elective modules were also produced to fulfill additional educa-
tional requirements for further specialization. Finally, a set of tools
for the implementation and assessment of shared quality stan-
dards were developed. In cooperation with other organizations,
two further programs having essentially similar education prin-
ciples were developed for teaching drug regulatory science and
TABLE 1 | Different medical needs of the various populations present in
LMIC’s.
Higher income population Low income population
Well educated Poorly educated
Can afford modern medical care May live in an unhygienic environment
and cannot afford modern medical care
Access to health-care is similar or
occasionally even better than in
developed countries. Demand and
require modern, well equipped medical
facilities and highly effective medicines
to treat broad range of illnesses.
Medical personnel who can apply
up-to-date treatment, can participate
in international trials and can organize
local clinical trials
Access to health-care is limited
Receives generally poorer medical care
since the delivery of modern
therapeutic methods is made difficult
due to large distances and a lack of
infrastructure. Suffers primarily from
communicable diseases. Special
organization and specially trained
personnel is needed to treat NCD
affecting a large population
Regulatory Agency which can adequately handle both modern sophisticated
medicines and an increased work load caused by innovative and many
follow-on chemical and biological medicines
clinical investigation within the PhT cooperation (PhT Manual;
PharmaTrain, 2015a).
The IMI-PhT program was primarily developed for countries
having well developed, large innovative pharmaceutical industry
where many specialists of medicines development and regulation
require high level education for efficiently participating in the very
competitive industrial working environment. It was obvious that
this elaborate program cannot be transferred in its original form
to LMICs which have lesser developed pharmaceutical industries,
regulatory agencies and a smaller number of trained clinical
investigators. To provide useful training for these communities
it is a necessary first step to adapt the PhT educational concept
and materials to the individual needs of the targeted countries.
Furthermore, in preliminary consultations it was unanimously
agreed that medicines development, regulatory science and clin-
ical investigation must be taught in conjunction with each other;
high level local medical research and efficient drug therapy can
be promoted only if these three equally important and mutually
supportive pillars are built in parallel. The meeting focused on
postgraduate education designed for experts who have previously
finished higher level training. However, it was acknowledged that,
especially in some low income countries, local workers with lesser
qualification must also be trained to initiate local activities.
In the introductory lecture Kerpel-Fronius explained the ratio-
nal for concentrating the discussion on issues primarily related
to medicines for non-communicable diseases (NCD) like cardio-
vascular diseases, diabetes, cancer, etc. This decision was based on
the rapidly changing composition of the local population which
leads to stratified needs for medical care (Table 1). The com-
municable diseases require specific scientific attention, including
the discovery and development of new medicines, large scale
epidemiologic interventions, primary preventions, etc. Generally
these topics are addressed by disease oriented projects sponsored
by various organizations. Their educational programs have to be
evaluated and tailored individually according to the nature of the
disease. In parallel with improving economies a rapidly emerging
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urban population with increased life expectancy has been devel-
oping in LMICs in recent years. They live in an improved environ-
ment, suffer increasingly from NCD and have expanding access
to higher quality, more sophisticated medical care using modern
equipment and innovative medicines. Nevertheless, according to
the data of the WHO, 85% of premature deaths from NCDs
occur in developing countries (WHO, 2013b). The availability of
modern medicines must therefore be improved, their regulatory
approval must be accelerated and finally their proper use by med-
ical staff must be evaluated and practiced within the local health
care infrastructure. Special attention must be given to the major
safety and regulatory problems presented by the new biological
medicinal agents and their follow-on biosimilar preparations pro-
duced in many countries in very different qualities. Hospitals and
regulatory agencies need additional well trained experts to handle
these agents properly.
According to Dodoo from Ghana the environment is ripe
for the development and deployment of new health technolo-
gies in LMICs. In general, commitments are plenty; however,
few countries have either qualitatively or quantitatively ade-
quate capacity for drug/vaccine testing and regulation. Although
partnerships are urgently required to perform these tasks, the
emerging economies cannot leave the development of viable and
locally-relevant solutions to external partners only. More special-
ists in drug development and regulation are urgently needed in
Africa. To reach this goal, besides specialists in molecular biol-
ogy, immunology, and pharmacology, statisticians, pharmaco-
and health care economists, lawyers, and ethicists have to be
trained to deal with both the scientific and related social, legal
issues of medical care. All stakeholders in such training must
ensure that the programs are relevant, useful, cost-effective and
modular to enable training alongside working. Finally the courses
should provide internationally acceptable certificates. According
to Dodoo, training institutions in emerging economies have to get
involved in practical day-to-day activities of the respective agen-
cies, companies and departments dealing with drug discovery,
research and regulation. Effective cooperation between the indus-
try, healthcare centers and government is essential to reach these
goals. Efforts should be made to ensure that any approach uti-
lized is sustainable and cost-effective. Continent-wide initiatives,
when properly harnessed, have the highest chance of success and
sustainability.
Dealing with specific healthcare problems and related educa-
tional activities in LMICs is an area in which the Bill & Melinda
Gates Foundation has a long and outstanding track record. For
many years it has supported global health product development
networks built on partnership, expertise, promoting improved
performance and the right products for the right patients at
the right time. The primary aim of the Integrated Development
Group is to augment the capabilities of program strategy teams
and partners with end-to-end product development. It promotes
integrated medicines development combining quantitative sci-
ences, regulatory affairs, diagnostics, chemistry, manufacturing
and controls. Several educational collaborations with many out-
standing scientific organizations have been organized to teach
clinical pharmacology, clinical and regulatory sciences (Bill &
Melinda Gates Foundation, 2015).
Competencies Needed Locally. Availability
of Educational Infrastructure and Activities
for Providing Advanced Continuous Professional
Training in Medicines Development
Current problems with professional training inmedicine develop-
ment were addressed by Silva. He stated that there is a perceived
mismatch between the profile of graduates from academic pro-
grams in the health care professions and the changing needs of the
various health systems around the world. Professional education
has not kept pace with these changes, largely because of frag-
mented, outdated and static curricula that produce ill-equipped
graduates. Redesign of professional health education is thus nec-
essary and timely. Usually, needs-oriented competence training
is done within the framework of post-graduate and interprofes-
sional education, where organizers of the various courses have
much more freedom to combine different scientific disciplines
and practical professional experience. The final goal should be
to achieve the required competencies defined as “an observable
ability of any professional, integrating multiple components such
as knowledge, skills, values, and attitudes” (Frank et al., 2010).
The main advantage of such competence based education is that
the competencies of a given profession can be assessed to ensure
their acquisition. Unfortunately the number of such courses in
medicine development is low world-wide, and their scientific
value and quality is frequently less well controlled compared to
graduate education.
An IFAPP-Pharmatrain organized working group identified
seven core competency domains for pharmaceutical medicine:
discovery and early drug development; clinical development and
clinical trials; medicines regulation; drug safety surveillance;
ethics and subject protection; health care market place and finally
communication and management skills. A total of 60 core com-
petencies for Pharmaceutical Physicians and Drug Development
Scientists were included within such domains and a Statement
of Competence was prepared. Finally, the Learning Outcomes of
the PharmaTrain Base Course were successfully aligned with the
above mentioned competencies (Silva et al., 2013). Many other
groups active in various fields of clinical research also defined
their relevant competencies. These were recently aligned and
harmonized by a Joint Task Force into a Harmonized Core Com-
petency Framework for Clinical Research Professionals (Sonstein
et al., 2014). It was concluded by the participants that the number
of courses offered as part of the continuous professional devel-
opment programs have to be increased and thoroughly planned
to provide the necessary competencies aligned with the specific
needs of LMICs. Further the needs may change over time. There-
fore, a single approach for education and training is not feasible.
The educational needs of the targeted populations should always
be considered.
The advantages of e-learning were repeatedly emphasized since
this method provides the broadest andmost rapid access to teach-
ing material worldwide. According to Whitty the availability of
the internet seems not to be an issue in most places anymore.
He pointed out that e-learning is especially suitable for post-
graduate education since these trainees’ exhibit a special attitude
to learning. Frequently they study besides working, come with
different skills and life experience, are more autonomous adults,
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and their outcome expectations are different from those of grad-
uate students. They are more goal oriented, so consequently the
learning content must be relevant and practical enough to be used
immediately in their jobs. According to his experience, blended
learning, combining e-teaching material with tutorial support, is
especially successful and leads to much higher completion rates
compared to automated CPD.
Massud reported that in South America post-graduate training
in pharmaceutical medicine is offered in Brazil, Argentina and
Mexico. In the last two countries pharmaceutical medicine is
accepted as a medical specialty. However, generally, medicines
development and clinical pharmacology training at the univer-
sities are not considered as a priority. There is limited avail-
ability of postgraduate education for clinical investigators in the
region. Most clinical research is carried out at the universities
where the investigators aremore science- thanmedicinal product-
orientated. One post-graduate course in pharmaceutical medicine
is offered in Brazil for which the initiation of an accreditation
process by PharmaTrain is planned. A comparative evaluation of
the training needs listed by people working in medicine develop-
ment in Brazil and Peru showed interesting country differences
in educational needs (Silva et al., 2014). More importantly, a
very high need for training in business and management skills
was registered in both countries. It is obvious that these subjects
should be incorporated into the training programs of medicines
development.
Rosenkranz discussed the important role played by South
Africa in the development of new medicines on the African
continent. Clinical trials (phase I–IV) have a long tradition in
South Africa, and their number is rapidly increasing, with an
estimated present value of about 1.3–2 billion Euro generated
annually (Kahn and Gastrow, 2008). The typical patient popu-
lations available in first-world countries can also be accessed in
SouthAfrica.Due to the considerable burden of disease forHIVor
TB, these patient populations are also available. Clinical trials are
performed according to internationally accepted medical, ethical
and regulatory standards. Clinical research in sub-Saharan Africa
is mainly performed by international and local companies, but
increasingly also by clinicians in the form of investigator-initiated
trials in order to address gaps in knowledge about specific treat-
ment requirements in the region. However, there is a clear need
for more and better clinical research conducted in Africa, which
should focus more evenly on the major contributors to burden of
disease in this part of the world (Isaakidis et al., 2002; Siegfried
et al., 2005).
Regulatory science and medicines development are not taught
at undergraduate level in South Africa. However, several universi-
ties have developed bachelor and/or master courses, in regulatory
science, drug development, pharmacoeconomics, pharmacovig-
ilance, and pharmaceutical affairs. In 2010 a fully accredited
2 year diploma program in medicines development was started
at the Division of Clinical Pharmacology, Stellenbosch Univer-
sity following the PhT concept, and a master’s program will be
initiated in 2015. This program was accredited by PharmaTrain
as a Center of Excellence in May 2014, as the first non-European
training course. Non-academic training programs and workshops
in medicines development and drug regulation are offered by the
Fundisa African Academy of Medicines Development (FAAMD).
Clinical Pharmacology has been recognized as a full medical
specialty since 2009, comprising one of the Colleges of Medicine
in South Africa (CMSA). In 2011, the UK Faculty of Pharma-
ceutical Medicine has exported its medical specialty examination,
the Diploma in Pharmaceutical Medicine, to South Africa and
Singapore. In South Africa, physicians working in the pharmaceu-
tical industry are organized in the South African Association of
Pharmaceutical Physicians [SAAPP] (under review) which had 83
members in 2005; this organization is currently being re-activated.
The clinical research is organized in the South African Clinical
Research Association (SACRA).
Unfortunately neither of these regionally-established courses
attracts larger numbers of students from the neighboring coun-
tries, although this would be very helpful for promotingmedicines
research and regulation in smaller, lesser developed countries of
the respective geographical regions. In Central-Eastern Europe
this problem is being overcome by organizing an international-
regional approach, primarily to offer easily accessible, relatively
inexpensive international education for students working in sev-
eral neighboring countries. Additionally, the course accepts stu-
dents from all countries world-wide. The Cooperative European
Medicine Development Course [CEMDC] (2015) organized with
the support of the IMI-PhT program is an educational network in
which 10 universities from 10 countries are cooperating. The edu-
cational program is jointly planned by the universities, and coor-
dinated by the Semmelweis University in Hungary, which also
issues the diplomas on behalf of the Kerpel-Fronius (2014) and
Cooperative EuropeanMedicine Development Course [CEMDC]
(2015). It was proposed that the organization of such regional
networks could be both economically and scientifically very help-
ful also in LMIC’s for pulling together both the students and
the local trainers as well as the scarce financial resources from a
geographical area (Cooperative EuropeanMedicine Development
Course [CEMDC], 2015).
The Increased Qualitative and Quantitative
Challenges of the Local Drug Regulatory
Agencies
The increasing complexity of new therapeutic interventions, the
new types of medicinal agents developed in recent years, presents
a great challenge for competent authorities. Regulators can solve
these problems only through increased collaboration between
the various disciplines and extensive networking. Bass reported
that, linked to the IMI-PhT project, a modular Master’s Pro-
gram in Medicine Regulatory Affairs was organized jointly by
the universities of Basel, Copenhagen and Kings College, Lon-
don, in collaboration with several other organizations. The aim
is to provide regulatory, industry and university professionals
with a comprehensive understanding of the rapidly expanding
regulatory requirements for medicines development and lifecycle
management, along with competence to apply them. He suggested
that similar cooperative regulatory educational programs would
be needed also in emerging economies, since both the number
of new, high tech medicinal products submitted for registra-
tion, as well as the local participation in international medicine
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development trials, will increase considerably in these regions. In
addition they have to inspect drug manufacturing, and control
international trade of medicinal products and active substances.
An immediate solution might be to organize close cooperation
between foreign competent authorities. However, the primary
goal must be to train local experts by either sending them abroad
to learn or, preferably, to establish local courses with international
and national trainers.
In South Africa, The Medicines Control Council (MCC) is
the statutory body that regulates new active substances, generic
medicines and biologicals including vaccines, and oversees clini-
cal trials as well as post-marketing variations. Hela explained that
its present working model relies on external reviewers recruited
mainly from universities and research institutions. This leads to
long review timelines and little predictability when reviews will
be completed. Over time, the workload has increased and become
more complex, due to an increase in the number of regulatory sub-
missions, particularly of generic medicines and post-marketing
variation applications. In addition, the role of the regulator has
expanded from its original focus on allopathic medicines to the
inclusion of poorly regulated and unregulated commodities, e.g.
complementary and alternative medicines, African Traditional
Medicines, medical devices and in vitro diagnostics, food and
cosmetics. As a consequence, it has been recognized that there is
a need for a different regulatory model. A review of the MCC has
been conducted with recommendations on strengthening internal
capacity. Legislative amendments to this end are quite advanced
and will lead to the formation of a new Agency, the South African
Health Products Regulatory Agency (SAHPRA). The workload
will be managed with a mixture of internally and externally
performed reviews, with different proportions according to the
various modules. A critical mass of capable reviewers is required
to carry out the regulator’s mandate and obligations of ensur-
ing timely access to safe, efficacious and quality commodities.
This Agency therefore will require a new model of staff training,
emphasizing capacity building through on the job training and
ad hoc short courses. The need for training of regulatory experts
in South Africa was assessed in a report prepared by the EU-
funded Ecorys Health Consortium. They proposed establishment
of a Regulatory Science Institute for coordinating training that
should serve both the Agency and the industry in the region. A
blended learning platform was recommended since on the job
training alone is lengthy and takesmuch time from the established
experts. The necessary training should be based on a gap analysis
and be organized in cooperation with the universities and other
training providers. Mentorship should also be introduced. Using
thismodel the time for obtaining the necessary competencemight
be decreased from 18 to 24 months to about 6 months.
The recommendations for the SouthAfrican regulatoryAgency
are relevant also to other African countries. Kern called the atten-
tion of the participants to the “innovation lag” that impacts uptake
of new medicines, vaccines and medical innovations in LMIC’s.
For a variety of reasons, these innovations face delays of varying
and often unpredictable length before they are able to get to the
people who can benefit from them. One contributing factor is
the complex and un-harmonized regulatory process that exists for
these innovations to gain entry into LMICs.Months and years can
go by after innovations have already been approved by stringent
regulatory authorities from upper income countries before the
innovation receives prequalification from the WHO and local
country regulatory approval. This impacts the ability of LMIC’s
to both procure these innovations and distribute them to their
citizens. The recently initiated WHO Collaborative Registration
Procedure enables the exchange of confidential information about
products, controlled according to the WHO Prequalification of
Medicines Programme (PQP). The countries participating in the
collaborative registration commit themselves for a national regis-
tration timeline of 90 days (WHO, 2013a). Related to this program
the Bill & Melinda Gates Foundation (2015) facilitated with other
partners and national governments the formation of six regional
African regulatory harmonization blocks. As part of the program
44 harmonized guidelines and requirements were developed and
underwent full approval at theministerial level. It was proven that,
through a joint registration procedure, the time to reach the mar-
ket could be significantly decreased. It was extensively discussed
that there are especially few experts who are able to deal with
the new complex biological drugs in emerging countries (Matsoso
et al., 2015). Not surprisingly theWHOpromotes the formation of
multinational organizations formaking the regulatory evaluations
jointly for countries in a given region (Rago, 2014).
The Education of Clinical Investigators, Ethical
Committees
Themerits of an online professional community to provide afford-
able training around the globe for those working in clinical trials
was convincingly demonstrated by Allen. Research in resource-
limited settings has suggested that addressing technical compe-
tence, trial-specific training, knowledge-sharing, and experience-
exchange for clinical investigators are key factors which would
enable an increase in their confidence and motivation. The Glob-
alHealthTrials.org website, part of a broader Global Health Net-
work, provides a forum to address these issues for clinical inves-
tigators and their teams. Sophisticated digital technology brings
free, open access, peer-reviewed e-learning products and a profes-
sional membership scheme that supports career development in
clinical trials. Since its start in May 2010 by Oxford University the
website has become widely popular, with 230,000 visits recorded
to date. It works well in practice since it addresses all regions,
all staff roles and all disease areas. Furthermore it is democratic,
neutral and does not belong to any one institution.
The concept and organization of the European Clinical
Research Infrastructure Network (ECRIN) was demonstrated by
Demotes-Mainard as a possible example to be copied in other
geographical regions. The primary aim of this organization is to
provide scientific and organizational background for performing
non-industry funded clinical trials. These community sponsored
trials are very important to address clinically relevant problems
which are not directly related to marketing authorization of new
medicines. Presently 23 countries are participating in the network.
The elaborate organization provides information and consultancy
during the preparation of trials and services during their conduct.
A review carried out in the involved countries showed that for the
clinical trials of new drugs the requirements for study initiation
are very complex but quite similar. However, for medical devices,
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clinical trials in various clinical specialties and diagnostic studies
the relevant obligations are very different,making an international
study more difficult (Gluud et al., 2012). ECRIN, together with
several organizations, advocate a risk-based regulatory and ethical
oversight to ease the initiation of clinical trials not investigating
new chemical entities. The OECD Global Science Forum works
along the same principles and intends to globalize a concept essen-
tially similar to that built in Europe (OECDGlobal Science Forum,
2011). Such global networking will be very helpful for involving
many LMICs in large international non-industry sponsored clin-
ical trials. In addition such regional network organizations might
offer an excellent opportunity to perform studies of local medical
relevance.
European Clinical Research Infrastructure Network (ECRIN)
also champions a three tiered concept for training clinical investi-
gators that was developed jointly with PhT. The first level contains
all the basic ethical and scientific information needed for new
clinical investigators as well as for the supporting hospital staff.
The second level provides more complex information concerning
trial management and regulatory requirements for experienced
local chief investigators. Finally the third tier was conceived
for coordinating investigators and deals with complex design of
multicenter, multinational trials, together with the underlying
international regulatory framework (Boeynaems et al., 2013). The
Clinical Investigator Certificate (CLIC) educational concept can
be very easily adjusted to the local conditions due to its stratified
organization of knowledge.
In recent years clinical trials investigating targeted and
advanced therapies considerably increased the scientific knowl-
edge necessary for appropriate ethical review. The need for train-
ing of ethical committee members was repeatedly pointed out.
In addition, Kerpel-Fronius mentioned that the increasing use
of human biopsy materials in clinical trials requires appraising
the impact of the planned research project on the human rights
of the trial subjects. He recommended creating single united
national ethical committees in LMICs instead ofmultiple commit-
tees working at the different universities. The major advantage of
such centralized ethical evaluation of the clinical research projects
is that the necessary expertise can be pulled together from the
entire country. In addition a national ethical committee can better
control that ethical principles are uniformly applied. Such a sys-
tem works excellently in Hungary. However, it was pointed out
by Massud that the experience with a central ethical committee
providing only guidelines for the local active ethical committees
is unsatisfactory in Brazil. It seems therefore to be important to
elucidate further the possible advantages, the necessary statutes
and organization for optimal scientific functioning of central ethi-
cal committees. Regionalmultinational ethical committees are not
advocated due to the variations in the national legal framework,
which makes joint ethical decisions practically impossible.
Quality Assurance
The need for good a quality management system is of paramount
importance for all levels of education. The quality principles
worked out by the IMI Education and Training projects were pre-
sented byDubois. They essentially state that the training should be
offered on an equality basis, the courses should encourage a mul-
tidisciplinary approach and should be transparent regarding con-
flict of interest. The teaching staff should be well trained, and the
methods and facilities should be adequate to support the acquisi-
tion of the aimed knowledge and competency (Klech et al., 2012).
Considering that e-learning is becoming more popular, addi-
tional quality standards were developed for this type of education.
For broad application these programs should be platform inde-
pendent, easy to use, reliable, securely defended by a firewall
policy and, if required, could be applied for virtual classroom
teaching. In addition they should fulfill the following e-quality
standards:
 Blended levels of interactivity to be available. This can be either
face-to-face combined with internet-based, or internet-based
with integrated live activity.
 System in place for online practice exercises.
 Archiving policy to be defined to allow repeated viewings
and/or spreading modules over time.
 System in place for obtaining feedback in conjunction with
self-assessment questions (e.g., tutor availability to review
questions after assessment is completed).
 Standards for tutorial activities (responsibilities, organization
and implementation).
It was emphasized that adherence to these quality standards is
essential at any place where an educational program is organized.
Only qualitatively well-controlled education can provide interna-
tionally accepted certificates which are desired by the attendees
of courses presented in LMICs. Finally it is evident that the joint
efforts of the local and international teams are needed for the
satisfactory compliance with these criteria.
Discussion
A short workshop can only provide a sketch of the complex reality
which must be filled in with the necessary details by subsequent
activities of teams providing educational programs in LMICs.
Nevertheless, themain outlines of the educational needs for devel-
oping and regulatingmedicines efficiently in emerging economies
could be clearly formulated. It was unanimously accepted that par-
allel with the improving economy a rapidly increasing urbanized
population emerges. They have a longer life expectancy and suffer
increasingly from the same NCD present in developed countries.
They need modern therapeutic interventions, including innova-
tive and follow-on drugs introduced in richer countries. However,
neither the health care and regulatory infrastructure, nor the num-
ber of well-educated personnel, is adequate tomeet this enormous
challenge. Therefore, the main focus of future education must
be the rapid expansion of the number of various types of local
experts trained in medicines development, regulations, and clin-
ical research, respectively. These differently educated specialists
should become able in a concerted effort to participate in the
international and local development of new drugs, to guarantee
their rapid regulatory acceptance and finally to apply them safely
and efficiently at the bed side.
It was also pointed out by the participants that, to achieve these
goals, training must be multidisciplinary for supporting equal
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development of these scientific disciplines. The education must
be competence-oriented and fulfill the local needs. The medicine
development, regulatory, and clinical research educational pro-
grams recently harmonized within the European IMI-PhT project
can satisfy these expectations according to the experience
obtained in differently developed regions of the world. The pro-
grams can be relatively easily transferred from Europe to any
country since they cover all the important relevant topics, are
organized in a separately presentable modular structure, and have
defined module-specific learning outcomes leading to the desired
competence. This conceptual organization is a great help in the
proper alignment of the programwith the local requirements since
the different modules and topics can be easily rearranged and
combined into the desired teaching program. Naturally, an addi-
tional adjustment to the educational background of the audience
will be always needed. The importance of the availability of proper
quality standards were emphasized by the participants since they
are the guarantee for delivering internationally acceptable high
level education in any country.
An important discussion point was to define the desired out-
comes of the educational efforts. It was suggested that all the
various programs should support the organization of scientifically
well prepared program strategy teams, in which the partners are
able to perform end-to-end product development. It was further
emphasized that regional cooperation in all these scientific areas
is of paramount importance. The experience of theWHOand sev-
eral locally active organizations indicates that only a cooperative
regional-multinational approach can efficiently bring together the
number of differently qualified personnel necessary to handle
rapidly complex issues. The participation of international experts
in such regional working groups is not only helpful but is a very
efficient approach to provide hand-on training to local colleagues.
This suggestion is also true for the ethical review of increasingly
complex clinical trials. International clinical research, regulatory
and educational networks established in Europe and elsewhere
might serve as useful examples to develop regional organizations
also LMICs.
The final conclusion and message of the workshop is that the
rapid economic and sociological changes which have occurred
in the LMICs have transformed the health care and regulatory
environment to an extent which makes the direct transfer of
sophisticated knowledge acquired in the developed countries nec-
essary and possible. Competence-oriented, modular educational
programs for supporting these efforts are now available. They
only need to be aligned with the local needs. To follow up this
conclusion the PharmaTrain Federation and IFAPP formed a
joint working group to translate this conclusion into practice.
Efforts are underway to develop cooperation with local experts
and institutions as well as with international organizations active
in supporting health care in LMICs.
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